ADL
RNAM

Asset Dedication LLC’s Avidity Biosciences RNAM Stock Holding History

Asset Dedication LLC’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2
Closed – – 1112
2022
Q3 		$0 Hold
2
– – ﹤0.01% 995
2022
Q2 		$0 Hold
2
– – ﹤0.01% 868
2022
Q1 		$0 Buy
+2
New +$34 ﹤0.01% 1045

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Asset Dedication LLC's RNAM Position: Q4 2022 in Review

Asset Dedication LLC sold out of Avidity Biosciences (RNAM) in Q4 2022, closing a stake of 2 shares.

Asset Dedication LLC first reported a position in RNAM in Q1 2022 and held it in 3 quarters. The position peaked at $0 in Q3 2022. 148 funds tracked by Wall St. Rank hold RNAM as of Q4 2022.

  • Asset Dedication LLC reported no remaining Avidity Biosciences position as of Q4 2022 after selling out during the quarter.
  • Asset Dedication LLC sold 2 Avidity Biosciences shares in Q4 2022.
  • Asset Dedication LLC first reported a position in Avidity Biosciences in Q1 2022 and held it in 3 quarters.
  • Asset Dedication LLC's Avidity Biosciences position peaked at $0 in Q3 2022.
  • 148 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2022.

Based on Asset Dedication LLC's 13F filing for Q4 2022, filed 19 Jan 2023.